Ebb & Flow

So far, the 2003 IPO window is all talk and no action, with 10 companies waiting to see if they can go public. Still, most polled at last week's NewsMakers conference remain sanguine that the market could price the first biotech IPO this month or in early October.

William Kent, director at TF/Carson, the co-organizer of NewsMakers with BioCentury, said he is seeing heavy interest in cancer vaccine play CancerVax, in-licensor Pharmion and cardiovascular play Myogen...